The connection between GRKs and various signaling pathways involved in diabetic nephropathy

Wang, Feng-Ling; Tang, Li-Qin; Wei, Wei
July 2012
Molecular Biology Reports;Jul2012, Vol. 39 Issue 7, p7717
Academic Journal
Diabetic nephropathy (DN) is a known microvascular complication in patients with diabetes mellitus. DN has become one of the main causes of death in diabetic patients. The occurrence and development of DN results from the comprehensive action of multi-factors, though the exact mechanism is not very clear. Recently, a study found that numerous pathways are activated during the course of the disease, including the PGE2-EP-G protein system, the renin-angiotensin system, protein kinase C, MAPK and oxidative stress, and transforming growth factor-β. G protein-coupled receptor kinases (GRKs), specifically recognize and phosphorylate agonist-activated G protein-coupled receptors, which play a major role in the above-mentioned pathways. The purpose of this paper is to review current information concerning the connection between GRKs and various signaling pathways involved in DN.


Related Articles

  • Inhibition of the renin–angiotensin system: is more better? Anderson, Sharon; Komers, Radko // Kidney International;Jan2009, Vol. 75 Issue 1, p12 

    Inhibitors of the renin–angiotensin–aldosterone system (RAS) exert beneficial effects in diabetic nephropathy, but the possibility of regression of existing renal lesions remains to be investigated. Teles et al. tested the effects of the RAS inhibitor losartan in rats starting 10...

  • Podocyte ACE2 protects against diabetic nephropathy. Harris, Raymond C // Kidney International;Aug2012, Vol. 82 Issue 3, p255 

    As new components of the renin-angiotensin system (RAS) are elucidated, our understanding of the complexities of their interactions also advances. Previous studies have determined that podocytes possess a local RAS that can generate angiotensin II. Podocytes have also been shown to express...

  • Alterations of intrarenal renin-angiotensin and nitric oxide systems in streptozotocin-induced diabetic rats. Ki Chul Choi; Nam Ho Kim; Mi Ra An; Dae Gill Kang; Soo Wan Kim; Jong-un Lee // Kidney International Supplement;Sep1997, Issue 60, pS-23 

    Investigates the changes in the renin-angiotensin and nitric oxide (NO) systems in the early phase of diabetes. Determination of the protein levels of different isoforms of NO synthases by Northern and Western blot analyses; Injection of male Sprague-Dawley rats with streptozotocin; Measurement...

  • Angiotensin II receptor antagonists in hypertension. Burnier, Michel; Brunner, Hans R. // Kidney International;Dec1998 Supplement 68, Vol. 54, pS107 

    Angiotensin II receptor antagonists in hypertension. Blockade of the renin-angiotensin system is now recognized as an effective approach to the treatment of hypertension and congestive heart failure. Today, it is possible to antagonize the effects of angiotensin II more specifically by blocking...

  • Complete Blockade of the Renin-Angiotensin System in Patients With Advanced Diabetic Nephropathy. Deira, Javier; Diaz, Hugo; Grande, Jesús // Diabetes Care;May2003, Vol. 26 Issue 5, p1635 

    Comments on an article by K. Rossing and colleagues on the complete blockade of the renin-angiotensin system in patients with advanced diabetic nephropathy. Study of patients on prior treatment with ACE inhibitors; Calculation of glomerular filtration rate; Decrease in proteinuria and in total...

  • Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Jacobsen, Peter; Andersen, Steen; Rossing, Kasper; Jensen, Berit R.; Parving, Hans-Henrik // Kidney International;May2003, Vol. 63 Issue 5, p1874 

    Background: Albuminuria and hypertension are predictors of poor renal and cardiovascular outcome in diabetic patients. We tested whether dual blockade of the renin-angiotensin system (RAS) with both an angiotensin-converting enzyme (ACE) inhibitor and an angiotensin II receptor...

  • Autophagy: A Novel Therapeutic Target for Diabetic Nephropathy. Shinji Kume; Daisuke Koya // Diabetes & Metabolism Journal;Dec2015, Vol. 39 Issue 6, p451 

    Diabetic nephropathy is a leading cause of end stage renal disease and its occurance is increasing worldwide. The most effective treatment strategy for the condition is intensive treatment to strictly control glycemia and blood pressure using renin-angiotensin system inhibitors. However, a...

  • Present and Future in the Treatment of Diabetic Kidney Disease. Quiroga, Borja; Arroyo, David; de Arriba, Gabriel // Journal of Diabetes Research;4/7/2015, Vol. 2015, p1 

    Diabetic kidney disease is the leading cause of end-stage renal disease. Albuminuria is recognized as the most important prognostic factor for chronic kidney disease progression. For this reason, blockade of renin-angiotensin system remains the main recommended strategy, with either angiotensin...

  • Local delivery of angiotensin receptor blocker into the kidney ameliorates progression of experimental glomerulonephritis. Mahmood, J.; Khan, F.; Okada, S.; Kumagai, N.; Morioka, T.; Oite, T. // Kidney International;Nov2006, Vol. 70 Issue 9, p1591 

    Intrarenally synthesized angiotensin II (Ang II) may be involved in the progression of glomerulonephritis, leading to irreversible glomerulosclerosis. There is increasing evidence that systemic angiotensin receptor blocker (ARB) treatment has beneficial effect on the prognosis of progressive...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics